Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × itacitinib × 90 days × Clear all
NCT05757219 2026-03-31

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡